Immunotherapy of Ovarian Cancer

  • Steve Nicholson


There is no established role for immunotherapy in the management of epithelial ovarian cancer. The amount of research in this area is extensive, however, with some reports predating the introduction of efficacious platinum-based chemotherapy. The goals remain an improvement in response rates and (more realistically) the maintenance of responses by immunological means. An overview of both conventional ovarian cancer management and the immune environment of the peritoneum is provided before detailing clinical trial results and considering future developments.


Ovarian Cancer Ovarian Carcinoma Epithelial Ovarian Cancer Minimal Residual Disease Ovarian Cancer Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Griffiths C. Surgical resection of tumour bulk in the primary treatment of ovarian carcinoma. NCI Monograph 1975;42:101.Google Scholar
  2. 2.
    Luesley D Lawton F Blackledge G Hilton, C Kelly, K Rollason, et al. Failure of second-look laparotomy to influence survival in epithelial ovarian cancer. Lancet 2 1988;(8611):599–603.PubMedCrossRefGoogle Scholar
  3. 3.
    van der Burg M, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995;332:629–34.PubMedCrossRefGoogle Scholar
  4. 4.
    Vergote I, Vergote-De Vos L, Abeler V, et al. Randomised trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 1992;69:741–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Dembo, AJ. Abdominopelvic radiotherapy in ovarian cancer. A 10-year experience. Cancer 1985;55 (9 Suppl):2285–90.PubMedCrossRefGoogle Scholar
  6. 6.
    Lambert HE, Rustin GJ, Gregory WM, Nelstrop AE. A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: a North Thames Ovary Group study. J Clin Oncol 1993;11(3):440–8.PubMedGoogle Scholar
  7. 7.
    McGuire WP, Hoskins WJ. Brady MF, Kucera PR, Partridge EE Look, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer [see comments]. N Engl J Med 1996;334(1):1–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Sandercock J, Parmar M, Torri V. First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence. Br J Cancer 1998;78(11):1471–8.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Stuart G, Bertelsen K, Mangioni C, Trope C, James K, Cassidy J. et al. Updated analysis shows a highly significant improved overall survival (OS) for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish Intergroup trial. Los Angeles: American Society of Clinical Oncology, 1998.Google Scholar
  10. 10.
    Harper P. A Randomised Comparison of Paclitaxel (T) and Carboplatin (J) Versus a Control Arm of Single Agent Carboplatin (J) or CAP (cyclophosphamide, Doxorubicin and Cisplatin): 2075 Patients Randomised Into the 3rd International Collaborative Ovarian Neoplasm Study (ICON3). Atlanta, Georgeia: American Society of Clinical Oncology, 1999.Google Scholar
  11. 11.
    Adams M, Calvert A, Carmichael J, Clark P, Coleman R, Earl H, et al. Chemotherapy for ovarian cancer-a concensus statement on standard practice. Br J Cancer 1998;78(11):1404–6.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Kubicka U, Olszewski WL, Tarnowski W, Bielecki K, Ziolkowska A, Wierzbicki Z. Normal human immune peritoneal cells: subpopulations and functional characteristics. Scand J Immunol 1996;44(2):157–63.PubMedCrossRefGoogle Scholar
  13. 13.
    Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. New Engl J Med 1990;322(15):1021–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Hacker NF, Berek JS, Pretorius RG, Zuckerman J, Eisenkop S, Lagasse LD. Intraperitoneal cis-platinum as salvage therapy for refractory epithelial ovarin cancer. Obstet Gynecol 1987;70(5):759–64.PubMedGoogle Scholar
  15. 15.
    Campora E, Bruzzone M, Chiara S, Alama A, Iskra L, Carnino F, et al. Intraperitoneal cytosine arabinoside administered in sequence with systemic cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. Gynecol Oncol 1990;37(1):39–43.CrossRefGoogle Scholar
  16. 16.
    Kirmani S, McVey L, Loo D, Howell SB. A phase I clinical trial of intraperitoneal thiotepa for refractory ovarian cancer. Gynecol Oncol 1990;36(3):331–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Pfeiffer P, Bennedbaek O, Bertelsen K. Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancer. Gynecol Oncol 1990;36(3):306–11.PubMedCrossRefGoogle Scholar
  18. 18.
    Dufour P, Bergerat JP, Barats JC, Giron C, Duclos B, Dellenbach P, et al. Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. Cancer 1994;73(7):1865–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Markman M. Intraperitoneal paclitaxel in the management of ovarian cancer. Semin Oncol. Seminars in Oncology 1995;22(5):86–7.PubMedGoogle Scholar
  20. 20.
    Chambers SK, Chambers JT, Davis CA, Kohorn EI, Schwartz PE, Lorber MI, et al. Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine in refractory ovarian cancer patients. J Clin Oncol. Journal of Clinical Oncology 1997;15(5):1945–52.Google Scholar
  21. 21.
    Alberts DS, Liu PY, Hannigan EV, O’Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. New Engl J Med. New England Journal of Medicine 1996;335(26):1950–5.CrossRefGoogle Scholar
  22. 22.
    Eischen A, Duclos B, Schmitt-Goguel M, Rouyer N, Bergerat JP, Hummel M, et al. Human resident peritoneal macrophages: phenotype and biology. Br J Haematol 1994;88(4):712–22.PubMedCrossRefGoogle Scholar
  23. 23.
    Stuart AE, Davidson AE. The handling of antigen-antibody complexes and of antigen by human peritoneal cells in vitro. J Pathol 1971;104(1):37–43.PubMedCrossRefGoogle Scholar
  24. 24.
    Hartman J, Maassen V, Rieber P, Fricke H. T lymphocytes from normal human peritoneum are phenotypically different from their counterparts in peripheral blood and CD3-lymphocyte subsets contain mRNA for the recombination activating gene RAG-1. Eur J Immunol 1995;25(9):2626–31.PubMedCrossRefGoogle Scholar
  25. 25.
    Birkhofer A, Rehbock J, Fricke H. T lymphocytes from the normal human peritoneum contain high frequencies of Th2-type CD8+ T cells. Eur J Immunol 1996;26(4):957–60.PubMedCrossRefGoogle Scholar
  26. 26.
    Lue C, van-den-Wall-Bake AW, Prince SJ, Julian BA, Tseng ML, Radl J, et al. Intraperitoneal immunization of human subjects with tetanus toxoid induces specific antibody-secreting cells in the peritoneal cavity and in the circulation, but fails to elicit a secretory IgA response. Clin Exp Immunol 1994;96(2):356–63.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Hardin JA, Yamaguchi K, Sherr DH. The role of peritoneal stromal cells in the survival of sIgM + peritoneal B lymphocyte populations. Cell Immunol 1995;161(1):50–60.PubMedCrossRefGoogle Scholar
  28. 28.
    Perkins KA, Chain BM. Presentation by peritoneal macrophages: modulation by antibody-antigen complexes. Immunology 1986;58(1):15–21.PubMedCentralPubMedGoogle Scholar
  29. 29.
    Alberts D, Mason-Liddil N, O’Toole R, Abbott T, Kronmal R, Hilgers R, et al. Randomized phase III trial of chemoimmunotherapy in patients with previously untreated stages III and IV suboptimal disease ovarian cancer: a Southwest Oncology Group Study. Gynecol Oncol 1989;32(1):8–15.PubMedCrossRefGoogle Scholar
  30. 30.
    Creasman W, Omura G, Brady M, Yordan E, DiSaia P, Beecham J. A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1990;39(3):239–43.PubMedCrossRefGoogle Scholar
  31. 31.
    Rao B, Wanebo H, Ochoa MJ, Lewis JJ, Oettgen H. Intravenous Corynebacterium parvum: an adjunct to chemotherapy for resistant advanced ovarian cancer. Cancer 1972;39(2):514–26.CrossRefGoogle Scholar
  32. 32.
    Barlow J, Piver M, Lele S. High-dose methotrexate with “RESCUE” plus cyclophosphamide as initial chemotherapy in ovarian adenocarcinoma. A randomized trial with observations on the influence of C parvum immunotherapy. Cancer 1980;46(6):1333–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Bast RJ, Berek J, Obrist R, Griffiths C, Berkowitz R, Hacker N, et al. Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum. Cancer Res 193;43:1395–401.Google Scholar
  34. 34.
    Kawagoe K, Masuda H. Advanced ovarian cancer treated by intraperitoneal immunotherapy with OK-432. Jap J Clin Oncol 1986;16(2):137–42.Google Scholar
  35. 35.
    Mallmann P, Krebs D. Investigations on cell-mediated immunity in patients with breast and ovarian carcinomas receiving a combination of chemotherapy and immunotherapy with thymopentin. Methods & Findings Exp Clin Pharm 1990;12(5):333–40.Google Scholar
  36. 36.
    Inoue M, Tanaka Y, Sugita N, Yamasaki M, Yamanaka T, Minagawa J, et al. Improvement of longterm prognosis in patients with ovarian cancers by adjuvant sizofiran immunotherapy: a prospective randomized controlled study. Biotherapy 1993;6(1):13–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Chen I, Hasumi K. Activation of peritoneal macrophages in patients with gynecological malignancies by sizofiran and recombinant interferon-gamma. Biotherapy 1993;6(3):189–94.PubMedCrossRefGoogle Scholar
  38. 38.
    Koelbl H, Micksche M, Gitsch G, Hanzal E, Nowotny C. Treatment with biologic response modifiers in patients with ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1991;41(1):64–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Lichtenstein A, Spina C, Berek J, Jung T, J Z. Intraperitoneal administration of human recombinant interferon-alpha in patients with ovarian cancer: effects on lymphocyte phenotype and cytotoxicity. Cancer Res 1988;48(20):5853–9.PubMedGoogle Scholar
  40. 40.
    Nicoletta MO, Fiorentino MV, Vinante O, Prosperi A, Tredese F, Tumolo S, et al. Experience with intraperitoneal alpha-2a interferon. Oncology Switzerland 1992;49(6):467–73.CrossRefGoogle Scholar
  41. 41.
    Berek J, Stonebraker B, Lentz S, Adelson M, DeGeest K, Moore D. Intraperitoneal alpha-interferon in residual ovarian carcinoma: a phase II gynecologic oncology group study. Am Soc Clin Oncol, Los Angeles, 1998.Google Scholar
  42. 42.
    Willemse P, de Vries E, Mulder N, Aalders J, Bouma J, Sleijfer D. Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer. Eur J Cancer 1990;26(3):353–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Proietto A, Hacker NF. Intraperitoneal interferon-alpha-2b for patients with no macroscopic disease following second-look laparotomy. Int J Gynecol Cancer 1993;3(5):324–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Ferrari E, Maffeo DA, Graziano R, Gallo MS, Pignata S, De-Rosa L, et al. Intraperitoneal chemotherapy with carboplatin and recombinant interferon alpha in ovarian cancer. Eur J Gynaecol Oncol. European Journal of Gynaecological Oncology 1994;15(6):437–42.Google Scholar
  45. 45.
    Frasci G, Tortoriello A, Facchini G, Conforti S, Persico G, Mastrantonio P, et al. Carboplatin and alpha-2b interferon intraperitoneal combination as first-line treatment of minimal residual ovarian cancer. A pilot study. Eur J Cancer Part A Gen Top 1994;30(7):946–50.CrossRefGoogle Scholar
  46. 46.
    Bruzzone M, Rubagotti A, Gadducci A, Catsafados E, Foglia G, Brunetti I, et al. Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord Ovest. Gynecol Oncol 1997;65(3):499–505.Google Scholar
  47. 47.
    Rambaldi A, Introna M, Colotta F, Landolfo S, Colombo N, Mangioni C, et al. Intraperitoneal administration of interferon beta in ovarian cancer patients. Cancer 1995;56(2):294–301.CrossRefGoogle Scholar
  48. 48.
    Pujade-Lauraine E, Guastalla JP, Colombo N, Devillier P, Francois E, Fumoleau P, et al. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at secondlook laparotomy. J Clin Oncol 1996;14(2):343–50.PubMedGoogle Scholar
  49. 49.
    Windbichler G, Hausmaninger H, Stummvoll W, Graf A, Kainz C, Lahodny J, et al. Interferongamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 2000;82(6):1138–44.PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    Kamada M, Sakamoto Y, Furumoto H, Mori K, Daitoh T, Irahara M, et al. Treatment of malignant ascites with allogeneic and autologous lymphokine-activated killer cells. Gynecol Oncol 1989;34(1):34–7.PubMedCrossRefGoogle Scholar
  51. 51.
    Steis RG, Urba WJ, VanderMolen LA, Bookman MA, Smith-JW II, et al. Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. J Clin Oncol 1990;8(10):1618–29.PubMedGoogle Scholar
  52. 52.
    Stewart J, Hird V, Snook D, Dhokia B, Sivolapenko G, Hooker G, et al. Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. J Clin Oncol 1990;8(12):1941–50.PubMedGoogle Scholar
  53. 53.
    Freedman RS, Edwards CL, Kavanagh JJ, Kudelka AP, Katz RL, Carrasco CH, et al. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: A pilot trial. J Immunother 1994;16(3):198–210.CrossRefGoogle Scholar
  54. 54.
    Freedman RS, Gibbons JA, Giedlin M, Kudelka AP, Kavanagh JJ, Edwards CL, et al. Immunopharmacology and cytokine production of a low-dose schedule of intraperitoneally administered human recombinant interleukin-2 in patients with advanced epithelial ovarian carcinoma. J Immunother Emphasis Tumor Immunol 1996;19(6):443–51.PubMedCrossRefGoogle Scholar
  55. 55.
    Edwards R, Lembersky B, Kunschner A. Intraperitoneal interleukin-2 (IL-2) produces durable responses for refractory ovarian cancer. Am Soc Clin Oncol 1995.Google Scholar
  56. 56.
    Freedman R, Edwards C, Bowen J, Lotzova E, Katz R, Lewis E, et al. Viral oncolysates in patients with advanced ovarian cancer. Gynecol Oncol 1988;29(3):337–47.PubMedCrossRefGoogle Scholar
  57. 57.
    Hudson C, McHardy J, Curling O, English P, Levin L, Poulton T, et al. Active specific immunotherapy for ovarian cancer. Lancet 1976;ii:877–9.CrossRefGoogle Scholar
  58. 58.
    Gusdon JJ, Homesley H, Jobson V, Muss H. Treatment of advanced ovarian malignancy with chemoimmunotherapy using autologous tumor and Corynebacterium parvum. Obstet Gynecol 1983;62(6):728–35.PubMedGoogle Scholar
  59. 59.
    Yacyshyn M, Poppema S, Berg A, MacLean G, Reddish M, Meikle A, et al. CD69+ and HLA-DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy. Int J Cancer 1995;61(4):470–4.PubMedCrossRefGoogle Scholar
  60. 60.
    Ioannides C, Platsoucas C, Freedman R. Immunological effects of tumor vaccines: II. T cell responses directed against cellular antigens in the viral oncolysates. In Vivo 1990;4(1):17–24.PubMedGoogle Scholar
  61. 61.
    Bodmer WF, Browning MJ, Krausa P, Rowan A, Bicknell DC, Bodmer JG. Tumor escape from immune response by variation in HLA expression and other mechanisms. Ann N Y Acad Sci 1993;690:42–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Pai L, Bookman M, Ozols R, Young R, Smith Jd, Longo D, et al. Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J Clin Oncol 1991;9(12):2095–103.PubMedGoogle Scholar
  63. 63.
    Davies K, Hird V, Stewart S, Sivolapenko G, Jose P, Epenetos A, et al. A study of in vivo immune complex formation and clearance in man. J Immunol 1990;144:4613–20.PubMedGoogle Scholar
  64. 64.
    Jerne N. Towards a network theory of the immune system. Ann Immunol (Inst Pasteur) 1974;125C:373–89.Google Scholar
  65. 65.
    Bona C, Victor-Kobrin C, Manheimer A, Bellon B, Rubinstein L. Regulatory arms of the immune reponse. Immunol Rev 1984;79:25–44.PubMedCrossRefGoogle Scholar
  66. 66.
    Courtenay-Luck NS, Epenetos AA, Sivolapenko GB, Larche M, Barkans JR, Ritter MA. Development of anti-idiotypic antibodies against tumour antigens and autoantigens in ovarian cancer patients treated intraperitoneally with mouse monoclonal antibodies. Lancet 1988;2(8616):894–7.PubMedCrossRefGoogle Scholar
  67. 67.
    Baum R, Noujaim A, Nani A, Moebus V, Hertel A, Niesen A, et al. Clinical course of ovarian cancer patients under repeated stimulation of HAMA using MAb OC125 and B43.13. Hybridoma 1993;12(5):583–9.CrossRefGoogle Scholar
  68. 68.
    Baum RP, Niesen A, Hertel A, Nancy A, Hess H, Donnerstag B, et al. Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma. Cancer 1994;73(3 Suppl):1121–5.PubMedCrossRefGoogle Scholar
  69. 69.
    Madiyalakan R, Sykes T, Dharampaul S, Sykes C, Baum R, Hr G, et al. Anti-idiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CAl25 murine monoclonal antibody B43.13. Hybridoma 1995;14(2):199–203.PubMedCrossRefGoogle Scholar
  70. 70.
    Wagner U. Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma 1993;12(5):521–8.PubMedCrossRefGoogle Scholar
  71. 71.
    Medac. OVAREX (MAb-B43.13). A murine monoclonal antibody for the immunotherapy and immunoscintigraphy of epithelial ovarian tumours, medac Gesellschaft fur klinische 1996.Google Scholar
  72. 72.
    Reinartz S, Boerner H, Koehler S, Von Ruecker A, Schlebusch H, U W. Evaluation of immunological responses in patients with ovarian cancer treated with the anti-idiotype vaccine ACA125 by determination of intracellular cytokines-a preliminary report. Hybridoma 1999;18(1):41–5.PubMedCrossRefGoogle Scholar
  73. 73.
    Bolhuis RL, Stoter G, Arienti F, Canevari S. Adoptive immunotherapy (Meeting abstract). Proc Annu Meet Am Assoc Cancer Res 1994.Google Scholar
  74. 74.
    Canevari S, Mezzanzanica D, Mazzoni A, Negri D, Ramakrishna V, Bolhuis R, et al. Bispecific antibody targeted T cell therapy of ovarian cancer: Clinical results and future directions. J Hematother 1995;4(5):423–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Canevari S, Stoter G, Arienti F, Bolis G, Colnaghi MI, Di RE, et al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 1995;87(19):1463–9.PubMedCrossRefGoogle Scholar
  76. 76.
    Mazzoni A, Mezzanzanica D, Jung G, Wolf H, Colnaghi M, Canevari S. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma. Cancer Res 1996;56(23):5443–9.PubMedGoogle Scholar
  77. 77.
    Stewart J, Hird V, Snook D, Sullivan M, Myers M, Epenetos A. Intraperitoneal 131I-and 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry. Int J Cancer Supp 1988;3:71–6.CrossRefGoogle Scholar
  78. 78.
    Buraggi GL, Crippa F, Gasparini M, Seregni E, Gavoni N, Marini A. Radioimmunotherapy of ovarian cancer with 1311 MOvI8: preliminary results (Meeting abstract). Fourth Annual Symposium: Current Status and Future Directions of Immunoconjugates. Diagnostic and Therapeutic Applications in Benign and Malignant Disorders 1992.Google Scholar
  79. 79.
    Crippa F, Bolis G, Seregni E, Gavoni N, Scarfone G, Ferraris C, et al. Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal-antibody i-131 mov18-clinical-results in patients with minimal residual disease of ovarian-cancer. Eur J Cancer 1995;31A(5):686–90.PubMedCrossRefGoogle Scholar
  80. 80.
    Stewart JA, Belinson JL, Moore AL, Dorighi JA, Grant BW, Haugh LD, et al. Phase I trial of intraperitoneal recombinant interleukin-2/Iymphokine-activated killer cells in patients with ovarian cancer. Cancer Res 1990;50(19):6302–10.PubMedGoogle Scholar
  81. 81.
    Jacobs AJ, Fer M, Su FM, Breitz H, Thompson J, Goodgold H, et al. A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: Toxicity and clinical response. Obstet Gynecol 1993;82(4):586–93.PubMedGoogle Scholar
  82. 82.
    Alvarez R, Partridge E, Khazaeli M, Plott G, Austin M, Kilgore L, et al. Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. Gynecol Oncol 1997;65:94–101.PubMedCrossRefGoogle Scholar
  83. 83.
    Meares C, McCall M, Rearden D, Goodwin D, Diamanti C, Mctigue M. Conjugation of antibodies with bifuncyional chelating agents:isothiocyanate and bromoacetamide reagents, methods of analysis and subsequent addition of metal ions. Anal Biochem 1984;142:68–78.PubMedCrossRefGoogle Scholar
  84. 84.
    Meares C, Moi M, Diril H, Kukis D, McCall M, Deshpande S, et al. Macrocyclic chelates of radiometals for diagnosis and therapy. Br J Cancer 1990;62(Suppl X):21–6.Google Scholar
  85. 85.
    Hird V, Maraveyas A, Snook D, Dhokia B, Soutter WP, Meares C, et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 1993;68(2):403–6.PubMedCentralPubMedCrossRefGoogle Scholar
  86. 86.
    Myers M. Dosimetry for radiolabelled antibodies-macro or micro? Int J Cancer Suppl 1988;2:71–3.PubMedCrossRefGoogle Scholar
  87. 87.
    Maraveyas A, Snook D, Hird V, Kosmas C, Meares CF, Lambert HE, et al. Pharmacokinetics and toxicity of an yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer. Cancer 1994;73(3 Suppl):1067–75.PubMedCrossRefGoogle Scholar
  88. 88.
    Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumour cell-dendritic cell hybrids. Nature Med 2000;6(3):332–6.PubMedCrossRefGoogle Scholar
  89. 89.
    Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000;96:3102–8.PubMedGoogle Scholar
  90. 90.
    Santin AD, Hermonat PL, Ravaggi A, Bellone S, Pecorelli S, Cannon MJ, Parham GP. In vitro induction of tumor-specific human lymphocyte antigen class 1-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. Am J Obstet Gynecol 2000;183:601–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2002

Authors and Affiliations

  • Steve Nicholson

There are no affiliations available

Personalised recommendations